OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
February 17, 2021
The acquisition will integrate drug substance, drug product, and clinical testing capabilities under Quotient.
September 28, 2020
GRAM is expanding fill/finish capacity and is working with Janssen on tech transfer in preparation for production of Janssen’s SARS-CoV-2 vaccine candidate at GRAM’s Grand Rapids, MI facility.
July 21, 2020
Catalent has unveiled investment plans to create a European center of excellence for clinical biologics formulation development and drug product fill/finish services.
July 08, 2020
The acquisition will give the CDMO additional clinical filling options in Europe, which is expected to come online in 2021.
July 01, 2020
The COVID-19 pandemic has created a rise in demand for R&D and a shift in focus for some contract organizations.
May 18, 2020
Vibalogics is contracted to manufacture Janssen's COVID-19 candidate vaccine at its GMP-accredited facility in Cuxhaven, Germany.
May 04, 2020
Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.
February 15, 2020
Technology and capacity investments create opportunities in the cell and gene therapy arena for CDMOs and biopharma alike.
February 01, 2020
CDMOs and CMOs will continue to invest in biopharmaceutical services and facilities as the bio/pharmaceutical industry looks to biosimilars and personalized medicine.
January 08, 2020
Catalent completes purchase of biologics fill-finish and oral solid dose facility in Anagni, Italy